Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 8/20 | 0.58 |
| ▸ | STAT6 | P42226 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CD38 | P28907 | 1/20 | 0.47 |
| ▸ | VNN1 | O95497 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 3/20 | 0.47 |
| ▸ | JAK1 | P23458 | 3/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22261161 | 0.91 | STAT6 (0.61) | JAK3STAT6JAK2JAK1 | |
| SCHEMBL22261262 | 0.90 | JAK3 (0.57) | JAK3STAT6MAPTCD38JAK2 | |
| SCHEMBL22261066 | 0.90 | JAK3 (0.56) | JAK3STAT6MAPTVNN1JAK2 | |
| SCHEMBL2387160 | 0.89 | STAT6 (0.61) | JAK3STAT6JAK2JAK1 | |
| SCHEMBL22261196 | 0.88 | JAK3 (0.55) | JAK3STAT6JAK2JAK1 | |
| SCHEMBL22261277 | 0.86 | JAK3 (0.59) | JAK3STAT6CD38VNN1JAK2 | |
| SCHEMBL22261393 | 0.86 | JAK3 (0.48) | JAK3STAT6MAPTJAK2JAK1 | |
| SCHEMBL22261125 | 0.85 | JAK3 (0.61) | JAK3STAT6CD38VNN1JAK2 | |
| SCHEMBL22261306 | 0.84 | JAK3 (0.58) | JAK3STAT6JAK2JAK1 | |
| SCHEMBL29622785 | 0.84 | JAK3 (0.58) | JAK3STAT6JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3686197-B1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-06-21 | — | — | EP | disclosed |
| US-11344549-B2 | 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20210077489-A1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2021-03-18 | — | — | US | disclosed |
| EP-3686197-A1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2020-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210077489-A1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | JAK1, JAK3, JAK2 | JAK3 2/4885STAT6 7/4885MAPT 3106/4885 |
| US-11344549-B2 | 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof | JAK1, JAK3, JAK2 | JAK3 2/4885STAT6 7/4885MAPT 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.